title: Neonatal neurosteroid levels are determinant in shaping adult prepulse inhibition response to hippocampal allopregnanolone in rats.
abstract: Diverse studies indicate that the alteration of the physiological levels of neurosteroids in early neonatal phases provokes alterations in the maturation of certain cerebral structures. Allopregnanolone (ALLO) has important modulatory effects in the hippocampus during the postnatal period where the adult pattern of inhibitory transmission is being established. In order to study whether endogenous neonatal ALLO levels would be a determinant parameter involved in mediating adult hippocampal GABAA system maturation, we investigated the effects of neonatal finasteride (50mg/kg, SC) treatment and ALLO (ALLO; 20mg/kg, SC) supplementation on an animal behavioural model with relevance to neurodevelopmental disorder, such as schizophrenia. Two sets of experiments were conducted. Neonatal treatment (from postnatal day (pnd) 5 to pnd9) was performed in 23 male Wistar rats and steroid quantification was performed in hippocampal homogenates at pnd9. A second group (n=127) underwent neonatal treatment (pnd5-pnd9) and were submitted to hippocampal surgery at 80d. The behavioural response to bilateral intrahippocampal neurosteroid administration (ALLO, 0.2μg/0.5μl per side or pregnenolone sulphate 5ng/0.5μl per side) on novelty-induced exploration activity and prepulse inhibition (PPI) was assessed at 95d. Results showed that neonatal ALLO and finasteride administration decreased novelty directed exploratory behaviour and impaired the prepulse inhibition of the acoustic startle response at 95 days of age. Moreover, intrahippocampal ALLO increased head-dipping behaviour independently of the neonatal treatment, while intrahippocampal ALLO decreased PPI only in finasteride and ALLO groups. The results obtained in the present study indicate the importance of neonatal neurosteroid levels in the development of hippocampal function and their relevance in a behavioural phenotype that some have likened to that present in schizophrenia.
authors.affiliation: Departament de Psicobiologia i Metodologia en Ciències de la Salut, Institut de Neurociències, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Valles, Campus de Bellaterra, Barcelona, Spain. sonia.darbra@uab.es
authors.forename: Sònia
authors.initials: S
authors.lastname: Darbra
authors.forename: Laura
authors.initials: L
authors.lastname: Modol
authors.forename: Monique
authors.initials: M
authors.lastname: Vallée
authors.forename: Marc
authors.initials: M
authors.lastname: Pallarès
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000494:pharmacology; D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D018120:Finasteride / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000494:pharmacology*; D011280:Pregnanolone / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D011284:Pregnenolone / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D013216:Reflex, Startle / Q000187:drug effects; D055139:Sensory Gating / Q000187:drug effects / Q000502:physiology*
chemical_list: D058891:5-alpha Reductase Inhibitors; D018377:Neurotransmitter Agents; D018120:Finasteride; D011284:Pregnenolone; D011280:Pregnanolone